机构：[1]Obstetrics and Gynecology Department, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, 1111 XianXia Road, Shanghai 200336, China.
Cervical cancer (CC) is the second most common female cancer. Excellent clinical outcomes have been achieved with current screening tests and medical treatments in the early stages, while the advanced stage has a poor prognosis. Nicotinamide adenine dinucleotide (NAD+) metabolism is implicated in cancer development and has been enhanced as a new therapeutic concept for cancer treatment. This study set out to identify an NAD+ metabolic-related gene signature for the prospect of cervical cancer survival and prognosis. Tissue profiles and clinical characteristics of 293 cervical cancer patients and normal tissues were downloaded from The Cancer Genome Atlas database to obtain NAD+ metabolic-related genes. Based on the differentially expressed NAD+ metabolic-related genes, cervical cancer patients were divided into two subgroups (Clusters 1 and 2) using consensus clustering. In total, 1404 differential genes were acquired from the clinical data of these two subgroups. From the NAD+ metabolic-related genes, 21 candidate NAD+ metabolic-related genes (ADAMTS10, ANGPTL5, APCDD1L, CCDC85A, CGREF1, CHRDL2, CRP, DENND5B, EFS, FGF8, P4HA3, PCDH20, PCDHAC2, RASGRF2, S100P, SLC19A3, SLC6A14, TESC, TFPI, TNMD, ZNF229) were considered independent indicators of cervical cancer prognosis through univariate and multivariate Cox regression analyses. The 21-gene signature was significantly different between the low- and high-risk groups in the training and validation datasets. Our work revealed the promising clinical prediction value of NAD+ metabolic-related genes in cervical cancer.
基金：
National Natural Science Foundation of China (No. 81903006).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2021]版：
大类|3 区医学
小类|3 区卫生保健与服务3 区医学：内科
最新[2023]版：
大类|3 区医学
小类|3 区医学：内科4 区卫生保健与服务
JCR分区：
出版当年[2020]版：
Q1HEALTH CARE SCIENCES & SERVICESQ1MEDICINE, GENERAL & INTERNAL
最新[2023]版：
Q1MEDICINE, GENERAL & INTERNALQ2HEALTH CARE SCIENCES & SERVICES
第一作者机构：[1]Obstetrics and Gynecology Department, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, 1111 XianXia Road, Shanghai 200336, China.
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Chen Aozheng,Jing Wanling,Qiu Jin,et al.Prediction of Cervical Cancer Outcome by Identifying and Validating a NAD+ Metabolism-Derived Gene Signature[J].JOURNAL OF PERSONALIZED MEDICINE.2022,12(12):doi:10.3390/jpm12122031.
APA：
Chen Aozheng,Jing Wanling,Qiu Jin&Zhang Runjie.(2022).Prediction of Cervical Cancer Outcome by Identifying and Validating a NAD+ Metabolism-Derived Gene Signature.JOURNAL OF PERSONALIZED MEDICINE,12,(12)
MLA：
Chen Aozheng,et al."Prediction of Cervical Cancer Outcome by Identifying and Validating a NAD+ Metabolism-Derived Gene Signature".JOURNAL OF PERSONALIZED MEDICINE 12..12(2022)
